Drug Profile
Research programme: pain therapy - EQiTX
Alternative Names: ZingoTXLatest Information Update: 13 Jul 2011
Price :
$50
*
At a glance
- Originator EQiTX
- Class
- Mechanism of Action TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 03 Aug 2005 This programme is available for licensing (http://www.eqitx.com)
- 03 Aug 2005 Preclinical trials in Pain in Australia (unspecified route)